Compare Eaton Corporation plc (ETN) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Twist Bioscience Corp — how do they compare? Eaton Corporation plc trades at $427.4 (market cap $164.88B), while Twist Bioscience Corp trades at $152.84 (market cap $10.08B). The key difference: Eaton Corporation plc is far larger — about 16.4× Twist Bioscience Corp's market cap, and Eaton Corporation plc pays a 1.04% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Twist Bioscience Corp for 27 Days on average.
| ETN | TWST | |
|---|---|---|
Market Cap | $164.88B | $10.08B |
Volume | 2,535,086 | 4,229,037 |
Sector | Industrials | Health |
52-Week High | $459.96 | $205.00 |
52-Week Low | $315.82 | $25.45 |
Typical Hold Time | 31 Days | 27 Days |
Enterprise Value | $185.51B | $10.01B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $431.33, down 3.09% today but maintains strong analyst support with 70% buy ratings. The company shows consistent earnings beats and robust profitability with 12.75% net margins. Technical indicators suggest a bullish trend with support at $426 and resistance at $434. Recent acquisitions in data center and utility markets position ETN for durable growth in key infrastructure sectors.
Outlook remains positive with a $502.38 consensus price target representing 16% upside. Key opportunities include data center demand and grid modernization, while risks involve execution of recent acquisitions and potential market volatility. The company's strong backlog and strategic positioning in high-growth infrastructure markets support continued investor confidence.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
